Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately owned biopharma company, today announced its receipt of Health Canada’s approval for the standard cultivation, standard processing and sale for medical purposes under the Cannabis Regulations. According to the update, the licenses are effective as of Nov. 20, 2020. Valid for a three-year period, the terms of the licenses include approval of a single-story production facility designed to support micropropagation tissue culture, organic cultivation, processing and medical sales requirements. Phase II plans include expansion of the research laboratory and controlled cultivation rooms, as well as the addition of a medical dispensary.
To view the full press release, visit https://ibn.fm/Mn2Kp
About Way2Grow Nurseries (“W2G”)
Way2Grow is a privately owned company in the cannabis industry. W2G began with an organic vision to help patients gain better access to high quality, consistent, organic botanical and pharmaceutical products. To achieve this vision, W2G developed a consistent phyto-pharmaceutical feedstock growth plan through the use of tissue culture and molecular biology. These methods allow for the standardization of the procedures used to ensure quality and consistency of W2G botanicals and future pharmaceuticals.
W2G’s extensive research and IP approach is focused on the development of several new plant-based cultivation techniques, hybrid cultivar development, genetic profiling and tissue culture. By developing a molecular breeding and genetics program, W2G can identify new bioactive compounds to determine interactions with specific genes responsible for chronic diseases. Way2Grow is located in Osoyoos, British Columbia, and is regulated under the Cannabis Act and the Cannabis Regulations (Canada).
For more information, visit the company’s website at www.W2G.ca.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.